Indication
Norwalk virus gastroenteritis
2 clinical trials
3 products
Clinical trial
Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine(Hansenula Polymorpha) in Healthy People Aged Aged From 6 Months to 59 YearsStatus: , Estimated PCD: 2024-02-28
Product
Norovirus Bivalent VaccineClinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha) in Healthy People Aged 6 Months to 13 YearsStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Product
placebo